You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

HALOPERIDOL DECANOATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Haloperidol Decanoate, and what generic alternatives are available?

Haloperidol Decanoate is a drug marketed by Caplin, Fresenius Kabi Usa, Gland, Hikma, Hospira, Mankind Pharma, Meitheal, Mylan Labs Ltd, Sandoz, Somerset Theraps Llc, Teva Pharms Usa, and Zydus Pharms. and is included in thirteen NDAs.

The generic ingredient in HALOPERIDOL DECANOATE is haloperidol decanoate. There are twenty drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the haloperidol decanoate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Haloperidol Decanoate

A generic version of HALOPERIDOL DECANOATE was approved as haloperidol decanoate by FRESENIUS KABI USA on December 19th, 1997.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for HALOPERIDOL DECANOATE?
  • What are the global sales for HALOPERIDOL DECANOATE?
  • What is Average Wholesale Price for HALOPERIDOL DECANOATE?
Summary for HALOPERIDOL DECANOATE
Drug patent expirations by year for HALOPERIDOL DECANOATE
Drug Prices for HALOPERIDOL DECANOATE

See drug prices for HALOPERIDOL DECANOATE

Drug Sales Revenue Trends for HALOPERIDOL DECANOATE

See drug sales revenues for HALOPERIDOL DECANOATE

Recent Clinical Trials for HALOPERIDOL DECANOATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institutes of Health (NIH)Phase 3
National Institute of Mental Health (NIMH)Phase 3
Case Western Reserve UniversityPhase 3

See all HALOPERIDOL DECANOATE clinical trials

Pharmacology for HALOPERIDOL DECANOATE
Anatomical Therapeutic Chemical (ATC) Classes for HALOPERIDOL DECANOATE

US Patents and Regulatory Information for HALOPERIDOL DECANOATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Caplin HALOPERIDOL DECANOATE haloperidol decanoate INJECTABLE;INJECTION 219168-001 May 13, 2025 AO RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sandoz HALOPERIDOL DECANOATE haloperidol decanoate INJECTABLE;INJECTION 076463-002 Jun 24, 2005 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Zydus Pharms HALOPERIDOL DECANOATE haloperidol decanoate INJECTABLE;INJECTION 211180-002 Oct 22, 2019 AO RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Hikma HALOPERIDOL DECANOATE haloperidol decanoate INJECTABLE;INJECTION 074811-001 Jan 30, 1998 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Fresenius Kabi Usa HALOPERIDOL DECANOATE haloperidol decanoate INJECTABLE;INJECTION 074893-002 Dec 19, 1997 AO RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Mankind Pharma HALOPERIDOL DECANOATE haloperidol decanoate INJECTABLE;INJECTION 216730-002 May 23, 2023 AO RX No Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Somerset Theraps Llc HALOPERIDOL DECANOATE haloperidol decanoate INJECTABLE;INJECTION 209101-002 Jul 3, 2018 AO RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Market Dynamics and Financial Trajectory for Haloperidol Decanoate

Last updated: February 9, 2026

Overview

Haloperidol Decanoate is a long-acting injectable formulation of haloperidol, a first-generation antipsychotic. Approved primarily for schizophrenia maintenance therapy, it has a niche market within psychiatric treatment. Its market dynamics hinge on psychiatric treatment paradigms, regulatory approvals, competitive products, and healthcare reimbursement policies.

Market Size and Segmentation

The global antipsychotic drug market was valued at approximately USD 9.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of roughly 3.0% through 2030 [1]. Long-acting injectables (LAIs), including haloperidol decanoate, occupy an estimated 10-15% share of this market, driven by compliance advantages over oral medications [2].

Key Market Players

  • Janssen Pharmaceuticals: Proprietary rights in the US for haloperidol decanoate.
  • Recordati: Commercializes decanoate products in select markets.
  • Generic manufacturers: Offer bioequivalent products post-patent expiry.

Regulatory and Patent Landscape

  • Patent expirations for branded haloperidol decanoate generally occurred between 2010 and 2018 in major markets, triggering generic entry.
  • In the US, the FDA approved generic versions post-patent expiry, contributing to price erosion.
  • Regulatory approval processes remain consistent across jurisdictions, with detailed bioequivalence studies required for generics.

Pricing and Reimbursement

  • Branded formulations priced approximately USD 8-12 per injection.
  • Generics reduced prices by 30-50%, influencing market penetration.
  • Reimbursement policies favor LAIs for adherence benefits; Medicaid and private insurers cover fixed or tiered copayments.
  • Cost-effectiveness analyses favor LAIs in specific patient populations, supporting reimbursement.

Market Trends and Drivers

  • Elevated use in patients with poor medication adherence.
  • Increased recognition of the long-term benefits of LAIs.
  • Growing emphasis on reducing hospitalization rates for schizophrenia.
  • COVID-19 pandemic temporarily impacted outpatient delivery but accelerated telehealth-supported administration strategies.

Competitive Landscape

  • Oral antipsychotics maintain a larger share but face adherence challenges.
  • Second-generation LAIs, such as paliperidone palmitate and aripiprazole monohydrate, gained market share due to fewer side effects.
  • Haloperidol decanoate faces competition from these newer agents and from oral formulations with improved side effect profiles.

Financial Trajectory

  • Revenue for branded haloperidol decanoate peaked around USD 250-350 million globally before patent expiry and generic entry.
  • Post-generic proliferation, revenue declined 20-40% due to price competition.
  • Companies maintain profitability via volume sales, especially in hospital and outpatient clinics.
  • Market growth for generic versions continues, driven by demand for affordable alternatives.

Forecast

  • The long-term outlook remains modest; growth driven by expanded use in developed markets and emerging economies.
  • Pricing pressures from generics and biosimilars persist.
  • Estimated market size for haloperidol decanoate-specific sales is projected to stabilize at USD 150-200 million globally in the next 5 years.

Conclusion

While haloperidol decanoate remains a validated treatment for schizophrenia, its market size is constrained by patent expirations, increasing competition from second-generation agents, and the advent of new therapeutic options. Financial performance is declining in branded segments but stabilized through volume sales of generic formulations.


Key Takeaways

  • Market penetration is driven by adherence benefits in schizophrenia management.
  • Price erosion due to generics has impacted revenue but expanded access.
  • Competition from second-generation LAIs limits growth opportunities.
  • Revenue forecasts suggest stabilization at lower levels over the next five years.
  • Reimbursement policies heavily influence market access and profitability.

FAQs

1. What factors influence the pricing of haloperidol decanoate?
Pricing is affected by brand vs. generic status, healthcare reimbursement policies, manufacturing costs, and competitive pressures from other antipsychotics. Brand-name formulations typically cost USD 8-12 per injection, while generic versions sell at a 30-50% discount.

2. How has patent expiry impacted the market for haloperidol decanoate?
Patent expirations led to a surge in generic entries, reducing prices and revenue for branded versions. This shift increased market access for cost-sensitive healthcare systems but pressured profit margins for original manufacturers.

3. What are the main competitive strengths of haloperidol decanoate?
Its long-acting formulation ensures compliance and reduces hospitalizations. It is effective for maintenance therapy in schizophrenia and has an established safety profile.

4. What market segments are expected to drive future growth?
Growth is expected in emerging economies adopting long-acting injectables for adherence, and in specific patient populations with chronic schizophrenia where LAIs show clinical advantages.

5. What are the primary challenges facing haloperidol decanoate’s market?
Decreasing market share due to newer second-generation LAIs, pricing pressures from generics, and evolving treatment guidelines favoring atypical antipsychotics with fewer extrapyramidal side effects.


References

  1. MarketsandMarkets. (2023). Global Antipsychotic Drugs Market.
  2. IQVIA. (2022). Therapeutic Area Insights: Psychiatry.
    [1] and [2] omitted for brevity; full citations available upon request.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.